Eli Lilly Retatrutide Achieves 22.6% Weight Loss in Phase 3 Trials
Eli Lilly announced positive results from two additional Phase 3 clinical trials for retatrutide, a next-generation obesity treatment administered once weekly, on the 23rd (US local time) according to CNBC. The trials demonstrated significant weight loss in patients with obesity-related
LucasBennett·1m ago
